In summary, we have demonstrated in the present study that scFv‐IL‐13Rα2‐CAR‐T cells can efficiently target IL‐13Rα2 overexpressing human tumour cells in vitro and in pre‐clinical models of human glioma cancers as the binding of our newer clone #14‐1 in scFv‐IL‐13Rα2‐ CAR construct is ∼5 times more than the previous clone #4.30, 65. This evidence concerns the gene IL13RA2 and neoplasm.